

## Curriculum Vitae (Yi-Hsiang Huang M.D. Ph.D.)



**Current address:** No. 201, Shih-Pai Road, Sec. 2, Taipei City 11217, Taiwan

**E-mail:** yhhuang@vghtpe.gov.tw

**DATE OF BIRTH:** February 20, 1966

### **EDUCATION**

**Ph.D.**, Institute of Clinical Medicine, School of Medicine, National Yang-Ming University. Taipei, Taiwan. Sep 2000 –Aug 2004

**M.D.**, College of Medicine, National Yang-Ming University. Taipei, Taiwan. Sep 1984-Jun 1991

### **POST-DOCTORAL TRAINING**

**Postdoctoral Fellow**, Vaccine Branch, National Cancer Institute, National Institute of Health. Bethesda, MD, USA

With Branch Chief **Dr. Jay A Berzofsky** Jan 2006-Jan 2007

### **EMPLOYMENT**

#### **Current position**

**Professor**, Institute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan February, 2011-

**Attending Physician**, Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taiwan October 1999-

#### **Previous**

Department of Medicine, Taipei Veterans General Hospital 1998-1999 Chief Resident /Fellow

Division of Gastroenterology, Taipei Veterans General Hospital 1996-1998 Chief Resident

Department of Medicine, Taipei Veterans General Hospital 1993-1996 Resident

Military Service 1991-1993

### **ACADEMIC APPOINTMENT**

**Professor**, Institute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, February 2011-

**Associate Professor**, Institute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, August 2007-January 2011

**Associate Professor**, Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, February 2005-July 2007

**Instructor**, Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, August 1999-January 2005

**Assistant Instructor**, Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, July 1993-August 1999

### **BOARD CERTIFICATION**

Board of Internal Medicine of Taiwan (No. 4601)

Board of The Gastroenterological Society of Taiwan (No. 813)

Board of The Digestive Endoscopy Society of Taiwan (No. 886023)

Certificate of Professor (No. 018452)

Certificate of Associate Professor (No. 032208)

Certificate of Instructor (No. 057382)

Certificate of Assistant Instructor (No. 38819)

### **HONORS AND AWARDS**

1. Research Award from the National Science Council, Executive Yuan, 1999,2000  
ROC
2. Academic Award of Prof. JL Sung's Research Foundation 2001
3. Physician Research Scholarships, Institute of Biomedical Science, 2000,2001,2003,2004  
Academic Sinica
4. Taiwan Merit Scholarship, National Science Council, ROC 2006
5. Best Research Paper Award, Taipei Veterans General Hospital. 2010

### **REVIEWER OF JOURNALS**

Gut (SCI), Clinical Gastroenterology and Hepatology (SCI), Journal of Gastroenterology and Hepatology (SCI), Liver International (SCI), Alimentary Pharmacology and Therapeutics (SCI), Journal of Medical Virology (SCI), Journal of Formosan Medical Association (SCI), Kaohsiung Journal of Medical Sciences (SCI), Journal of Chinese Medical Association (SCI)

## PUBLICATIONS

Refereed paper included in science citation index:

1. **Huang YH\***, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, Liu CY, Yang MH, Tzeng CH, Lee PC, Lin HC, Lee SD. A Randomized Controlled Trial of Entecavir Prophylaxis for Rituximab-associated Hepatitis B Virus Reactivation in Lymphoma Patients with Resolved Hepatitis B. **J Clin Oncol** (In revision) (**\*corresponding author**)
2. Lee IC, Lin CH, **Huang YH\***, Huo TI, Su CW, Hou MC, Huang HC, Lee KC, Chan CC, Lin MW, Lin HC, Lee SD. IL28B Polymorphism Correlates with Active Hepatitis in Patients with HBeAg-negative Chronic Hepatitis B. **PLoS One** 2013;8(2):e58071 (**\*corresponding author**)
3. Chan CC, Cheng LY, Lu J, **Huang YH\***, Chiou SH\*, Tasi PH, Hou TI, Lin HC, Lee FY. The Role of Interferon- $\gamma$  Inducible Protein-10 in Mice Model of Acute Liver Injury Post Induced Pluripotent Stem Cells Transplantation. **PLoS One** 2012;7(12):e50577 (**\*corresponding author**)
4. Lee KC, Chan CC, Yang YY, Hsieh YC, **Huang YH\***, Lin HC\*. Aliskiren attenuates chronic carbon tetrachloride-induced liver injury in mice. **Eur J Clin Invest.** 2012 Dec;42(12):1261-71. (**\*corresponding author**)
5. Hsu CY, Lee YH, Hsia CY, **Huang YH**, Su CW, Lin HC, Lee RC, Chiou YY, Lee FY, Huo TI. Performance status in patients with hepatocellular carcinoma: Determinants, prognostic impact and ability to improve the BCLC system. **Hepatology.** 2012 Jul 13. doi: 10.1002/hep.25950.
6. Lee IC, Huo TI, **Huang YH\***, Chao Y, Li CP, Lee PC, Chiang JH, Su CW, Lan KH, Yang CM, Wu JC, Lin HC, Lee SD. Trans-arterial Chemo-embolization Can Prolong Survival for Patients with Metastatic Hepatocellular Carcinoma: A Propensity Score Matching Analysis. **Hepatol Int.** 2012 Oct;6(4):753-762 (**\*corresponding author**)
7. Lee YH, Hsu CY, Hsia CY, **Huang YH**, Su CW, Lin HC, Loong CC, Chiou YY, Huo TI. Defining the severity of liver dysfunction in patients with hepatocellular carcinoma by the model for end-stage liver disease-derived systems. **Dig Liver Dis.** 2012 Oct;44(10):868-74
8. Lee YH, Hsu CY, **Huang YH**, Su CW, Lin HC, Lee RC, Chiou YY, Huo TI, Lee SD. Selecting a prognostic renal surrogate for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. **J Gastroenterol Hepatol.** 2012 Oct;27(10):1581-1588
9. Wu WC, Chiou YY, Hung HH, Kao WY, Chou YH, Su CW, Wu JC, Huo TI, **Huang YH**, Lee KC, Lin HC, Lee SD. Prognostic Significance of Computed Tomography Scan-derived Splenic Volume in Hepatocellular Carcinoma Treated With Radiofrequency Ablation. **J Clin Gastroenterol.** 2012 Oct;46(9):789-795.
10. Lee YH, Hsu CY, Hsia CY, **Huang YH**, Su CW, Lin HC, Chiou YY, Huo TI. A prognostic model for patients with hepatocellular carcinoma within the Milan criteria undergoing non-transplant therapies, based on 1106 patients. **Aliment Pharmacol Ther.** 2012 Sep;36(6):551-9
11. **Huang YH\***, Lin HC, Lee SD. Management of chemotherapy-induced hepatitis B virus reactivation. **J Chin Med Assoc** 2012 Aug;75(8): 359-362 (**Review article**) (**\*corresponding author**)
12. Kao WY, Chiou YY, Hung HH, Su CW, Chou YH, Wu JC, Huo TI, Huang YH, Wu WC, Lin HC, Lee SD. Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy. **Clin**

- Radiol.** 2012 May;67(5):429-36.
13. Hsu CY, Hsia CY, **Huang YH**, Su CW, Lin HC, Chiou YY, Lee RC, Lee FY, Huo TI, Lee SD. Differential prognostic impact of renal insufficiency on patients with hepatocellular carcinoma: a propensity score analysis and staging strategy. **J Gastroenterol Hepatol.** 2012 Apr;27(4):690-9.
  14. Hsu CY, Hsia CY, **Huang YH**, Su CW, Lin HC, Pai JT, Loong CC, Chiou YY, Lee RC, Lee FY, Huo TI, Lee SD. Comparison of Surgical Resection and Transarterial Chemoembolization for Hepatocellular Carcinoma beyond the Milan Criteria: A Propensity Score Analysis. **Ann Surg Oncol.** 2012 Mar;19(3):842-9.
  15. Chen MH, Hsiao LT, Chen MH, Tsai CY, **Huang YH**, Chou CT. Clinical significance of chronic hepatitis B virus infection in patients with primary Sjögren's syndrome. **Clin Rheumatol.** 2012 Feb;31(2):309-15.
  16. Kao WY, Chiou YY, Hung HH, Su CW, Chou YH, Huo TI, **Huang YH**, Wu WC, Lin HC, Lee SD, Wu JC. Younger Hepatocellular Carcinoma Patients Have Better Prognosis After Percutaneous Radiofrequency Ablation Therapy. **J Clin Gastroenterol.** 2012 Jan;46(1):62-70.
  17. Chan CC, Cheng LY, Lin CL, **Huang YH\***, Lin HC, Lee FY. The protective role of natural phytoalexin resveratrol on inflammation, fibrosis and regeneration in cholestatic liver injury. **Mol Nutr Food Res.** 2011 Dec;55(12):1841-9 (**\*corresponding author**)
  18. Lee IC, **Huang YH\***, Chan CC, Huo TI, Chu CJ, Lai CR, Lee PC, Su CW, Wu JC, Lin HC, Lee SD. Impact of body mass index and viral load on liver histology in hepatitis B e antigen-negative chronic hepatitis B. **Clinical Nutrition** 2011 Oct;30:647-652 (**\*corresponding author**)
  19. Tsai YJ, Hsu CY, **Huang YH**, Su CW, Lin HC, Lee RC, Chiang JH, Huo TI, Lee SD. Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma. **Hepatol Int.** 2011 Apr 30. [Epub ahead of print]
  20. Hsin IF, Hsu CY, Huang HC, **Huang YH**, Lin HC, Lee RC, Chiang JH, Lee FY, Huo TI, Lee SD. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction. **J Clin Gastroenterol.** 2011 Jul;45(6):556-62
  21. Kao WY, Chiou YY, Hung HH, Chou YH, Su CW, Wu JC, Huo TI, **Huang YH**, Lin HC, Lee SD. Risk factors for long-term prognosis in hepatocellular carcinoma after radiofrequency ablation therapy: the clinical implication of aspartate aminotransferase-platelet ratio index. **Eur J Gastroenterol Hepatol.** 2011 Jun;23(6):528-36.
  22. Hsu CY, **Huang YH**, Chiou YY, Su CW, Lin HC, Lee RC, Chiang JH, Huo TI, Lee FY, Lee SD. Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: A propensity score analysis. **Liver Transpl.** 2011 May;17(5):556-66
  23. Lee IC, Chan CC, **Huang YH\***, Huo TI, Chu CJ, Lai CR, Lee PC, Su CW, Hung HH, Wu JC, Lin HC, Lee SD. Comparative Analysis of Non-invasive Models to Predict Early Liver Fibrosis in Hepatitis B e Antigen-negative Chronic Hepatitis B. **J Clin Gastroenterol.** 2011 Mar;45(3):278-85 (**\*corresponding author**)
  24. Hung HH, Chiou YY, Hsia CY, Su CW, Chou YH, Chiang JH, Kao WY, Huo TI, **Huang YH**, Su YH, Lin HC, Lee SD, Wu JC. Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. **Clin Gastroenterol Hepatol.** 2011 Jan;9(1):79-86

25. Huo TI, Hsu CY, **Huang YH**, Su CW, Lin HC, Lee RC, Chiou YY, Chiang JH, Lee PC, Lee SD. Prognostic prediction across a gradient of total tumor volume in patients with hepatocellular carcinoma undergoing locoregional therapy. **BMC Gastroenterol.** 2010 Dec 31;10:146
26. Lee IC, **Huang YH\***, Chan CC, Huo TI, Chu CJ, Lai CR, Lee PC, Su CW, Hung HH, Wu JC, Lin HC, Lee SD. Correlation between clinical indication for treatment and liver histology in hepatitis B e antigen-negative chronic hepatitis B: a novel role of alpha-fetoprotein. **Liver Int.** 2010 Sep;30(8):1161-1168 (**\*corresponding author**)#
27. Hung HH, Su CW, Lai CR, Chau GY, Chan CC, **Huang YH**, Huo TI, Lee PC, Kao WY, Lee SD, Wu JC. Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinoma. **Hepatol Int.** 2010 Sep 24;4(4):691-9.
28. Hsu CY, **Huang YH**, Su CW, Chiang JH, Lin HC, Lee PC, Lee FY, Huo TI, Lee SD. Transarterial chemoembolization in patients with hepatocellular carcinoma and renal insufficiency. **J Clin Gastroenterol.** 2010 Sep;44:e171-e177
29. Hsu CY, **Huang YH**, Hsia CY, Su CW, Lin HC, Loong CC, Chiou YY, Chiang JH, Lee PC, Huo TI\*, Lee SD. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring system. **J Hepatol** 2010 Jul; 53:108-117#
30. Lee IC, **Huang YH\***, Chu CJ, Lee PC, Lin HC, Lee SD. Hepatitis B Virus Reactivation After 23 Months of Rituximab-based Chemotherapy in an HBsAg-negative, Anti-HBs-positive Patient With Follicular Lymphoma. **J Chin Med Assoc** 2010 Mar; 73:156-160 (**\*corresponding author**)
31. **Huang YH\***, Hung HH, Chan CC, Lai CR, Chu CJ, Huo TI, Lee PC, Su CW, Lan KH, Huang HC, Lee IC, Lin HC, Lee SD. Core Antigen Expression Is Associated with Hepatic Necroinflammation in e Antigen-negative Chronic Hepatitis B Patients with Low DNA Loads. **Clinical and Vaccine Immunology** 2010 Jun;17:1048-1053 (**\*corresponding author**)
32. Hsu CY, Hsia CY, **Huang YH**, Su CW, Lin HC, Lee PC, Loong CC, Chiang JH, Huo TI, Lee SD. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. **Cancer** 2010 Jun;116:3006-3014
33. Huo TI\*, Hsu CY, **Huang YH**, Hsia CY, Lin HC, Lee PC, Loong CC, Chiang JH, Chiou YY, Lee SD. Diabetes mellitus as an independent prognostic predictor and its association with renal dysfunction in patients with hepatocellular carcinoma. **Liver Int.** 2010 Feb;30(2):198-207 **The first three authors (T-I Huo, C-Y Hsu and Y-H Huang) contributed equally to this article (with Editorial Comments for the paper)**
34. Hsu CY, Lin HC, **Huang YH**, Su CW, Lee FY, Huo TI, Lee PC, Lee JY, Lee SD. Comparison of the model for end-stage liver disease (MELD), MELD-Na and MELDNa for outcome prediction in patients with acute decompensated hepatitis. **Dig Liver Dis.** 2010 Feb;42:137-42
35. Hsu CY, **Huang YH**, Su CW, Lin HC, Chiang JH, Lee PC, Lee FY, Huo TI\*, Lee SD. Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization. **Liver Int.** 2010 Jan;30:77-84
36. Wu JC\*, **Huang YH**, Chau GY, Su CW, Lai CR, Lee PC, Huo TI, Sheen IJ, Lee SD, Lui WY. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. **J Hepatol** 2009 Nov;51:890-897. **The first three authors (J-C Wu, Y-H**

**Huang and G-Y Chau) contributed equally to this article (with Editorial Comments for the paper)**

37. Huo TI\*, Hsia CY, **Huang YH**, Lin HC, Lee PC, Lui WY, Chiang JH, Chiou YY, Loong CC, Lee SD. Selecting a Short-term Prognostic Model for Hepatocellular Carcinoma: Comparison Between the Model for End-stage Liver Disease (MELD), MELD-sodium, and Five Cancer Staging Systems. **J Clin Gastroenterol**. 2009 Sep;43:773-81. **The first three authors (T.-I. Huo, C.-Y. Hsia, and Y.-H. Huang) contributed equally to this work.**
38. Su CW, Chan CC, Hung HH, Huo TI, **Huang YH**, Li CP, Lin HC, Tsay SH, Lee PC, Lee SD, Wu JC\*. Predictive Value of Aspartate Aminotransferase to Alanine Aminotransferase Ratio for Hepatic Fibrosis and Clinical Adverse Outcomes in Patients With Primary Biliary Cirrhosis. **J Clin Gastroenterol**. 2009 Oct;43:876-83.
39. **Huang YH**. 2009 Novel H1N1 Influenza: The Impact of Viral Genomic Reassortment on Immune Evasion and Vaccine Strategy. **J Chin Med Assoc** 2009 Jun;72:281-2 (**Editorial**)
40. Wu JM, **Huang YH\***, Lee PC, Lin HC, Lee SD. Fatal Reactivation of Hepatitis B Virus in a Patient Who Was Hepatitis B Surface Antigen Negative and Core Antibody Positive Prior to Receiving Chemotherapy for Non-Hodgkin's Lymphoma. **J Clin Gastroenterol** 2009 May-Jun; 43:496-498 (**\*corresponding author**).
41. Huo TI, **Huang YH**, Hsia CY, Su CW, Lin HC, Hsu CY, Lee PC, Lui WY, Loong CC, Chiang JH, Chiou YY, Lee SD. Characteristics and outcome of patients with dual hepatitis B and C-associated hepatocellular carcinoma: are they different from patients with single virus infection? **Liver Int**. 2009 May;29:767-73.
42. **Huang YH\***, Wu JC, Peng WL, Huo TI, Shih HH, Lan KH, Su CW, Lee SD. Generation of Cytotoxicity against Hepatitis Delta Virus Genotypes and Quasispecies by Epitope Modification. **J Hepatol** 2009 Apr;50:779-788 (**\*corresponding author**)
43. Su CW, Hung HH, Huo TI, **Huang YH**, Li CP, Lin HC, Lee CP, Lee SD, Wu JC\*. Natural History and Prognostic Factors of Primary Biliary Cirrhosis in Taiwan: A Follow-up study Up to 18 Years. **Liver Int**. 2008 Nov;28:1305-13.
44. Huo TI, Lin HC, Hsia CY, **Huang YH**, Wu JC, Chiang JH, Chiou YY, Lui WY, Lee PC, Lee SD. The MELD-Na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: A prospective survey. **Dig Liver Dis**. 2008 Nov;40:882-9.
45. Huo TI\*, **Huang YH**, Su CW, Lin HC, Chiang JH, Chiou YY, Huo SC, Lee PC, Lee SD. Validation of the HCC-MELD for dropout probability in patients with small hepatocellular carcinoma (HCC) undergoing locoregional therapy. **Clin Transplant**. 2008 Jul-Aug;22:469-75. **The first three authors (T.-I. Huo, Y.-H. Huang and C.-W. Su) have contributed equally to this work.**
46. Shih HH, Jeng KS, Syu WJ, **Huang YH**, Su CW, Peng WL, Sheen IJ, Wu JC\*. Hepatitis B surface antigen levels and sequences of natural hepatitis b virus variants influence the assembly and secretion of hepatitis d virus. **J Virol**. 2008 Mar;82:2250-64
47. Tang CP, Shiao YT, **Huang YH\***, Tsay SH, Huo TI, Wu JC, Lin HC, Lee SD. Cholestatic jaundice as the predominant presentation in a patient with autoimmune hepatitis. **J Chin Med Assoc** 2008 Jan;71:45-48 (**\*corresponding author**)
48. Su CW, Wu JC, Chiou YY, Tsay SH, Huo TI, **Huang YH**, Hung HH, Lin HC, Lee SD. Successful radiofrequency ablation therapy for hepatocellular carcinoma in a male patient with early stage primary biliary cirrhosis and positive serum hepatitis B core antibody. **J Chin Med Assoc**. 2008 Jan;71(1):40-44.

49. Huang YS\*, Su WJ, **Huang YH**, Chen CY, Chang FY, Lin HC, Lee SD. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. **J Hepatol.** 2007 Jul;47:128-34.
50. Huo TI\*, Hsia CY, Chu CJ, **Huang YH**, Lui WY, Wu JC, Lee PC, Chi CW, Lee SD. The predictive ability of serum alpha-fetoprotein for hepatocellular carcinoma is linked with the characteristics of the target population at surveillance. **J Surg Oncol.** 2007 Jun;95:645-51.
51. Huo TI\*, **Huang YH**, Chiang JH, Wu JC, Lee PC, Chi CW, Lee SD. Survival impact of delayed treatment in patients with hepatocellular carcinoma undergoing locoregional therapy: is there a lead-time bias? **Scand J Gastroenterol.** 2007 Apr;42:485-92.
52. Wang SY, Wu JC\*, Chiang TY, **Huang YH**, Su CW, Sheen IJ. Positive selection of hepatitis delta antigen in chronic hepatitis d patients. **J Virol.** 2007 May;81:4438-44.
53. Huo TI\*, **Huang YH**, Huang HC, Wu JC, Lee PC, Chang FY, Lee SD. Fever and infectious complications after percutaneous acetic acid injection therapy for hepatocellular carcinoma: incidence and risk factor analysis. **J Clin Gastroenterol.** 2006 Aug;40:639-42.
54. Huo TI\*, Lee PC, **Huang YH**, Wu JC, Lin HC, Chiang JH, Lee SD. The Sequential Changes of the Model for End-stage Liver Disease Score Correlate With the Severity of Liver Cirrhosis in Patients With Hepatocellular Carcinoma Undergoing Locoregional Therapy. **J Clin Gastroenterol** 2006 Jul;40:543-550.
55. Huo TI\*, Lin HC, **Huang YH**, Wu JC, Chiang JH, Lee PC, Lee SD. The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy. **Cancer** 2006 Jul;107:141-8.
56. Su CW, **Huang YH**, Huo TI, Shih HH, Sheen IJ, Chen SW, Lee PC, Lee SD, Wu JC\*. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. **Gastroenterology** 2006 June; 130:1625-1635
57. **Huang YH**, Wu JC\*, Chang TT, Sheen IJ, Huo TI, Lee PC, Su CW, Lee SD. Association of core promoter/precore mutations and viral loads in e antigen-negative chronic hepatitis B patients. **J Viral Hepatitis** 2006 May;13:336-342
58. Huo TI\*, **Huang YH**, Lin HC, Wu JC, Chiang JH, Lee PC, Chang FY, Lee SD. Proposal of a Modified Cancer of the Liver Italian Program Staging System Based on the Model for End-Stage Liver Disease for Patients with Hepatocellular Carcinoma Undergoing Loco-Regional Therapy. **Am J Gastroenterol** 2006 May;101:975-982
59. **Huang YH**, Wu JC\*, Chen SC, Chen CH, Chiang JH, Huo TI, Lee PC, Chang FY, Lee SD. Survival Benefit of Transcatheter Arterial Chemoembolization in Patients with Hepatocellular Carcinoma larger than 10cm in Diameter. **Aliment Pharmacol Ther** 2006 Jan;23:129-135
60. Shiau YT, **Huang YH**,\* Wu JC, Tao MH, Syu WJ, Chang FY, Lee SD. Analysis of humoral immunity of hepatitis D virus DNA vaccine generated in mice by different dosage, gene gun immunization and in vivo electroporation. **J Chin Med Assoc** 2006 Jan;69:7-13 (**\*corresponding author**)
61. Huo TI\*, **Huang YH**, Lee SD, Wu JC. Is there an ideal prognostic model for hepatocellular carcinoma? **Gut.** 2005 Sep;54:1348 (letter to editor)
62. **Huang YH**, Chen CH, Chang TT, Chen SC, Wang SY, Lee HS, Lin PW, Huang GT, Sheu JC, Tsai HM, Lee PC, Chau GY, Lui WY, Lee SD, Wu JC\*. Evaluation of predictive value of CLIP, Okuda, TNM and JIS staging systems for hepatocellular carcinoma

- patients undergoing surgery. **J Gastroenterol Hepatol** 2005 May;20:765-771
63. **Huang YH**, Wu JC\*, Chen CH, Chang TT, Lee PC, Chau GY, Lui WY, Chang FY, Lee SD. Comparison of recurrence after hepatic resection in patients with hepatitis B versus hepatitis C-related small hepatocellular carcinoma in hepatitis B virus endemic area. **Liver Int** 2005 Apr;25:236-241
  64. Huo TI\*, **Huang YH**, Wu JC. Percutaneous ablation therapy for hepatocellular carcinoma: current practice and future perspectives. **J Chin Med Assoc** 2005 Apr;68:155-9.
  65. **Huang YH**, Chen CH, Chang TT, Chen SC, Chiang JH, Lee HS, Lin PW, Huang GT, Sheu JC, Tsai HM, Lee PC, Huo TI, Lee SD, Wu JC\*. The role of transcatheter arterial embolization for patients with unresectable hepatocellular carcinoma: a nation-wide, multi-center study evaluated by cancer stages. **Aliment Pharmacol Ther** 2005 Mar;21:687-694
  66. Wu JC\*, Hsu SC, Wang SY, **Huang YH**, Sheen IJ, Shih HH, Syu WJ. "Defective" mutations of hepatitis D viruses in chronic hepatitis D patients. **World J Gastroenterol** 2005 Mar;11:1658-62.
  67. Huo TI\*, **Huang YH**. Staging for hepatocellular carcinoma: Treatment strategy matters. **Hepatology** 2005;41:678. (letter to editor)
  68. Huo TI\*, Wu JC, Lin HC, Lee FY, Hou MC, **Huang YH**, Lee PC, Chang FY, Lee SD. Determination of the optimal model for end-stage liver disease score in patients with small hepatocellular carcinoma undergoing loco-regional therapy. **Liver Transpl.** 2004 Dec;10:1507-13.
  69. **Huang YH**, Tao MH, Hu Cp, Syu WJ, Wu JC\*. Identification of Novel HLA-A\*0201-restricted CD8 t-cell epitopes on hepatitis delta virus. **J Gen Virol** 2004 Oct;85:3089-3098
  70. **Huang YH**, Chen CH, Chang TT, Chen SC, Wang SY, Lee PC, Lee HS, Lin PW, Huang GT, Sheu JC, Tsai HM, Chau GY, Chiang JH, Lui WY, Lee SD, Wu JC\*. The role of transcatheter arterial embolization in patients with resectable hepatocellular carcinoma: a nation-wide, multi-center study. **Liver Int** 2004 Oct;24:419-424
  71. Huo TI\*, Wu JC, Hsia CY, Chau GY, Lui WY, **Huang YH**, Lee PC, Chang FY, Lee SD. Hepatitis C Virus Infection is a Risk Factor for Tumor Recurrence after Resection of Small Hepatocellular Carcinomas. **World J Surg** 2004;28:787-91.
  72. Huo TI\*, Wu JC, Lui WY, **Huang YH**, Lee PC, Chiang JH, Chang FY, Lee SD. Differential mechanism and prognostic impact of diabetes mellitus on patients with hepatocellular carcinoma undergoing surgical and nonsurgical treatment. **Am J Gastroenterol** 2004;99:1479-1487.
  73. Huo T\*, **Huang YH**, Wu JC, Chiang JH, Lee PC, Chang FY, Lee SD. Comparison of transarterial chemoembolization and percutaneous acetic acid injection as the primary loco-regional therapy for unresectable hepatocellular carcinoma: a prospective survey. **Aliment Pharmacol Ther** 2004;19:1301-1308.
  74. Huo TI\*, Wu JC, **Huang YH**, Chiang JH, Lee PC, Chang FY, Lee SD. Acute renal failure after transarterial chemoembolization for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and long-term outcome. **Aliment Pharmacol Ther.** 2004;19:999-1007.
  75. Huo TI\*, **Huang YH**, Wu JC, Lee PC, Chang FY, Lee SD. Induction of complete tumor necrosis may reduce intrahepatic metastasis and prolong survival in patients with hepatocellular carcinoma undergoing locoregional therapy: a prospective study. **Ann Oncol.** 2004;15:775-80.



76. Huo TI\*, Lui WY, Wu JC, **Huang YH**, King KL, Loong CC, Lee PC, Chang FY, Lee SD. Deterioration of hepatic functional reserve in patients with hepatocellular carcinoma after resection: incidence, risk factors and association with intrahepatic tumor recurrence. **World J Surg** 2004;28:258-62.
77. Huo TI\*, **Huang YH**, Wu JC, Lee PC, Chang FY, Lee SD. Persistent retention of acetic acid is associated with complete tumor necrosis in patients with hepatocellular carcinoma undergoing percutaneous acetic acid injection. **Scand J Gastroenterol** 2004;39:168-73.
78. Huo TI\*, Wu JC, Lui WY, Lee RC, Loong CC, **Huang YH**, Tsay SH, Chang FY, Lee SD. Reliability of the contemporary radiology to measure tumor size of hepatocellular carcinoma in patients undergoing resection: limitations and clinical implications. **Scand J Gastroenterol** 2004;39:46-52.
79. Huo TI\*, **Huang YH**, Wu JC, Lee PC, Chang FY, Lee SD. Percutaneous injection therapy for hepatocellular carcinoma in patients with chronic renal insufficiency. **Eur J Gastroenterol Hepatol** 2004;16:325-331.
80. Huo TI\*, **Huang YH**, Lui WY, Wu JC, Lee PC, Chang FY, Lee SD. Selective prognostic impact of serum  $\alpha$ -fetoprotein level in patients with hepatocellular carcinoma: analysis of 543 patients in a single center. **Oncol Rep** 2004; 11:543-50.
81. Huo TI\*, Wu JC, Wu SI, Chang AL, Lin SK, Pan CH, **Huang YH**, Chang FY, Lee SD. Changing seroepidemiology of hepatitis B, C, and D virus infections in high-risk populations. **J Med Virol.** 2004;72:41-45.
82. **Huang YH**, Wu JC\*, Hsu SC, Syu WJ. Varied immunity generated in mice by DNA vaccines with large and small hepatitis delta antigens. **J Virol** 2003;77:12980-12985.
83. Huo TI\*, **Huang YH**, Wu JC, Chiang JH, Lee PC, Chang FY, Lee SD. Sequential transarterial chemoembolization and percutaneous acetic acid injection therapy versus repeated percutaneous acetic acid injection for unresectable hepatocellular carcinoma: a prospective study. **Ann Oncol.** 2003 Nov;14:1648-1653.
84. Huo TI\*, Lui WY, **Huang YH**, Chau GY, Wu JC, Lee PC, Chang FY, Lee SD. Diabetes mellitus is a risk factor for hepatic decompensation in patients with hepatocellular carcinoma undergoing resection: a longitudinal study. **Am J Gastroenterol** 2003;98:2293-2298.
85. Huo TI\*, Wu JC, Lui WY, Lee PC, **Huang YH**, Chau GY, Tsay SH, Chang FY, Lee SD. Diabetes mellitus is a recurrence-independent risk factor in patients with hepatitis B virus-related hepatocellular carcinoma undergoing resection. **Eur J Gastroenterol Hepatol.** 2003;15:1203-1208.
86. Huo TI\*, **Huang YH**, Wu JC, Lee PC, Chang FY, Lee SD. Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: a prospective study. **Scand J Gastroenterol** 2003 38:770-778
87. Huang YS\*, Chern HD, Wu JC, Chao Y, **Huang YH**, Chang FY, Lee SD. Polymorphism of the N-acetyltransferase 2 gene, red meat intake and the susceptibility of hepatocellular carcinoma. **Am J Gastroenterol** 2003;98:1417-1422.
88. **Huang YH**, Wu JC\*, Chang TT, Sheen IJ, Lee PC, Huo TI, Su CW, Wang YJ, Chang FY, Lee SD. Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan. **J Viral Hepatitis** 2003;10:277-284
89. Su CW, Wu JC\*, Huang YS, Huo TI, **Huang YH**, Lin CC, Chang FY, Lee SD. Comparison of clinical manifestations and epidemiology between acute hepatitis A and acute hepatitis E in Taiwan. **J Gastroenterol Hepatol** 2002;17:1187-1191.

90. Huo TI\*, **Huang YH**, Wu JC, Lee PC, Chang FY, Lee SD. Survival benefit of cirrhotic patients with hepatocellular carcinoma treated by percutaneous ethanol injection as a salvage therapy. **Scand J Gastroenterol** 2002;37:350-355
91. Lin CC, Wu JC\*, Chou YH, **Huang YH**, Chang FY, Lee SD. Hereditary hemorrhagic telangiectasia: demonstration of portosystemic venous shunts using power Doppler sonography and sonographically guided percutaneous transhepatic portovenography. **J Clin Ultrasound** 2001 Nov-Dec;29:517-22.
92. Lin CC, Wu JC\*, Chang TT, **Huang YH**, Wang YJ, Tsay SH, Chow NH, Chang FY, Lee SD. Long-term evaluation of recombinant interferon alpha2b in the treatment of patients with hepatitis B e antigen-negative chronic hepatitis B in Taiwan. **J Viral Hepatitis** 2001 Nov;8:438-46.
93. Lin CC, Wu JC\*, Huang DF, Huang YS, **Huang YH**, Huo TI, Chang FY, Lee SD. Ranitidine-related Stevens-Johnson syndrome in patients with severe liver diseases: a report of two cases. **J Gastroenterol Hepatol** 2001 Apr;16:481-483
94. Lin CC, Wu JC\*, Chang TT, Chang WY, Yu ML, Tam A, Wang SC, **Huang YH**, Chang FY, Lee SD. Diagnostic value of IgG and IgM anti-HEV tests based on HEV RNA in a non-endemic area. **J Clin Microbiol** 2000 Nov;38:3915-3918
95. **Huang YH**, Wu JC\*, Tao MH, Syu WJ, Hsu SC, Chi WK, Chang FY, Lee SD. DNA-based immunization produced Th1 immune responses to hepatitis delta virus in a mouse model. **Hepatology** 2000 July;32:104-110 (Cited by Schiff's diseases of the liver, ninth edition, Lippincott Williams & Wilkins, 2003)
96. **Huang YH**, Wu JC\*, Lui WY, Chau GY, Tsay SH, Chiang JH, King KL, Huo TI, Chang FY, Lee SD. A prospective case controlled trial of adjuvant chemotherapy after resection of hepatocellular carcinoma. **World J Surg** 2000 May;24:551-555
97. **Huang YH**, Wu JC\*, Lin CC, Sheng WY, Wang YJ, Chang FY, Lee SD. Prevalence and risk factor analysis of TTV infection in prostitutes. **J Med Virol** 2000 Apr;60:393-395
98. Wu JC\*, Chen CM, Chiang TY, Sheen IJ, Chen JY, Tsai WH, **Huang YH**, Lee SD. Clinical and epidemiological implications of swine hepatitis E virus infection. **J Med Virol** 2000 Feb;60:166-171
99. **Huang YH**, Wu JC\*, Chiang TY, Chan TJ, Huo TI, Huang YS, Hwang SJ, Chang FY, Lee SD. Detection and viral nucleotide sequence analysis of TT virus infection in acute fulminant and non-fulminant hepatitis. **J Viral Hepatitis** 2000 Jan;7: 56-63.
100. Wu JC\*, Chiang TY, Shiue WK, Wang SY, Sheen IJ, **Huang YH**, Syu WJ. Recombination of hepatitis D virus RNA sequences and its implications. **Mol Biol Evol** 1999 Nov;16:1622-1632.
101. **Huang YH**, Wu JC\*, Chau GY, Lui WY, King KL, Chiang JH, Yen SH, Sheng WY, Hou MC, Lu CL, Chang FY, Lee SD. Supportive treatment, resection and transcatheter arterial chemoembolization in resectable hepatocellular carcinoma: an analysis of survival in 419 patients. **Eur J Gastroenterol Hepatol** 1999;11:315-321
102. Wu JC\*, Huang IA, **Huang YH**, Chen JY, Sheen IJ. Mixed genotypes infection with hepatitis D virus. **J Med Virol** 1999; 57:64-67
103. Huo TI, Wu JC\*, **Huang YH**, Yang UC, Sheen IJ, Chang FY, Lee SD. Evidence of transmission of hepatitis B virus to spouses from sequence analysis of the viral genome. **J Gastroenterol Hepatol** 1998;13:1138-1142.
104. Wu JC\*, Chiang TY, **Huang YH**, Huo TI, Hwang SJ, Huang IS, Sheng WY, Lee SD. Prevalence, implication and viral nucleotide sequence analysis of GB virus-C/Hepatitis G virus infection in acute fulminant and non-fulminant hepatitis. **J Med Virol**

1998;56:118-122

105. **Huang YH**, Wu JC\*, Chau GY, Tsay SH, King KL, Sheng WY, Lui WY, Lee SD. Detection of serum hepatitis B, C, and D viral nucleic acids and its implication in hepatocellular carcinoma patients. **J Gastroenterol** 1998;33:512-516. (**with Editorial**)
106. **Huang YH**, Wu JC\*, Sheng WY, Huo TI, Chang FY, Lee SD. Diagnostic value of anti-hepatitis D virus (HDV) antibodies revisited: a study of total and IgM anti-HDV compared with detection of HDV-RNA by polymerase chain reaction. **J Gastroenterol Hepatol** 1998;13:57-61.
107. Wu JC\*, Sheng WY, **Huang YH**, Hwang SJ, Lee SD. Prevalence and risk factor analysis of GBV-C/HGV infection in prostitutes. **J Med Virol** 1997;52:83-85.

#### **Refereed paper not included in science citation index:**

1. Wu JM, **Huang YH\***, Yang CF, Lee PC, Chan CC, Lin HC. Acute exacerbation of chronic hepatitis B complicated with pure red cell aplasia: report of a case. *Gastroenterological Journal of Taiwan*. 2009 June; 26(2):195-201 (**\*corresponding author**)
2. Su CW, Wu JC\*, **Huang YH**, Huang YS, Chang FY, Lee SD. Zafirlukast-induced acute hepatitis. *Chin Med J (Taipei)* 2002;65:553-556.
3. Lin CC, Wu JC\*, Chang SC, **Huang YH**, Huo TI, Chang FY, Lee SD. Resolution of refractory hepatic hydrothorax after chemical pleurodesis with minocycline. *Chin Med J (Taipei)* 2000;63:704-709
4. Han HF, Wu JC\*, Huo TI, Kao KP, **Huang YH**, Chang FY, Lee SD. Chronic hepatitis B exacerbated by Guillain-Barre Syndrome: a report of two cases. *Chin Med J (Taipei)* 1999;62:652-656
5. **Huang YH**, Wu JC\*, Lu SN, Chiang TY, Chang FY, Lee SD. Phylogenetic analysis to document a common source of hepatitis D virus infection in a mother and her child. *Chin Med J (Taipei)* 1999;62:28-32
6. **Huang YH**, Lee CH, Wu JC\*, Wang YJ, Chang FY, Lee SD. Functional pancreatic islet cell tumors with liver metastasis: the role of cytoreductive surgery and transcatheter arterial chemoembolization: a report of five cases *Chin Med J (Taipei)* 1998;61:748-754

#### **Conference paper**

1. **Yi-Hsiang Huang**, Ying-Chung Hong, Liang-Tsai Hsiao, Tzeon-Jye Chiou, Cheng-Hwai Tzeng, Han-Chieh Lin, Shou-Dong Lee. Randomized controlled trial of prophylactic entecavir in hbsag-negative/anti-hbc-positive lymphoma patients undergoing rituximab-based chemotherapy: preliminary report. 47<sup>th</sup> Annual Meeting of the European Association for the Study of the Liver (The international liver congress 2012), Apr 18-22, 2012, Barcelona, Spain (**Poster** presentation #516)
2. **Yi-Hsiang Huang**, I-Cheng Lee, Teh-Ia Huo, Chien-Wei Su, Han-Chieh Lin, Shou-Dong Lee. Synergistic Effect of Body Mass Index and Viral Load on Liver Histology in Hepatitis B e Antigen-negative Chronic Hepatitis B. The Liver Meeting 2011 (The 62ed Annual Meeting of AASLD). San Francisco, California, Nov 4-8, 2011. (**Poster** presentation #1551)
3. **Yi-Hsiang Huang**, I-Cheng Lee, Che-Chang Chan, Teh-Ia Huo, Chien-Wei Su, Han-Chieh Lin, Shou-Dong Lee. Application of Alpha-fetoprotein to Identify Patients Who Need Antiviral Treatment in HBeAg-negative Chronic Hepatitis B. The 61st Annual Meeting of AASLD. Boston, Massachusetts, October 29 - November 2, 2010. (**Poster** presentation)

4. **Yi-Hsiang Huang**, I-Cheng Lee, The-Ia Huo, Yee Chao, Jen-Huey Chiang, Han-Chieh Lin, Shou-Dong Lee. Analysis of Survival for Patients with Metastatic Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization with or without Adjuvant Treatment. The International Liver Cancer Association Fourth Annual Conference. September 10-12, 2010, Montreal, Canada (**Poster** presentation)
5. **Huang YH**, Huo TI, Chan CC, Su CW, Chu CJ, Wu JC, Lin HC, Lee SD. Analysis of short-term survival of lamivudine treatment in patients with decompensated cirrhosis related to hepatitis B. The 20<sup>th</sup> Conference of the Asian Pacific Association for the Study of the Liver. 25-28 March 2010, Beijing China (**Top 10% poster presentation**)
6. **Huang YH**, Hung HH, Chan CC, Lai CR, Lin HC, Lee SD. The Expression of Intrahepatic HBV Core Antigen is Associated with Active Liver Inflammation in Low Viremic e Antigen-Negative Chronic Hepatitis B Patients. The 60th Annual Meeting of the AASLD, Boston, Massachusetts, October 30 - November 3, 2009. (**Poster** presentation)
7. **Huang YH**, Wu JC, Peng WL, Chan CC, Lee SD. Induction of cytotoxicity against mutated HBV YMDD epitopes in HLA-A2 transgenic mice. 44<sup>th</sup> Annual Meeting of the European Association for the Study of the Liver, 2009, Copenhagen, Denmark. (**Top 10% poster presentation**)
8. **Huang YH**, Wu JC, Peng WL, Shih HH, Lee SD. Generation Of Cytotoxicity Against Hepatitis Delta Virus Quasispecies By Epitope Modification. 44<sup>th</sup> Annual Meeting of the European Association for the Study of the Liver, 2009, Copenhagen, Denmark. (**Poster** presentation)
9. **Huang YH**, Wu JC, Peng WL, Chan CC, Lee SD. Induction of cytotoxicity against mutated HBV YMDD epitopes in HLA-A2 transgenic mice. The Gastroenterological Society of Taiwan 2009 Annual Convention
10. **Huang YH**. CTLs induced by enhanced HDV epitope produce cross-genotype cytotoxicity. Hong Kong-Shanghai International Liver Congress 2008, Hong Kong (**Oral** presentation)
11. **Huang YH**, Wu JC, Peng WL, Huo TI, Su CW, Lee SD. High-avidity CTLs Induced by Enhanced HDV Epitope Produce Cross-genotype Cytotoxicity. The Gastroenterological Society of Taiwan 2008 Annual Convention (**Oral** presentation)
12. **Huang YH**, Chen CH, Chang TT, Chen SC, Lee SD, Wu JC. The role of transcatheter arterial embolization for patients with unresectable hepatocellular carcinoma: a nation-wide, multi-center study. The Gastroenterological Society of Taiwan 2005 Annual Convention (**Oral** presentation)
13. **Huang YH**, Tao MH, Hu Cp, Syu WJ, Wu JC. Identification of Novel HLA-A\*0201-restricted CD8 T-cell Epitopes on Hepatitis Delta Virus and their implications in chronic delta hepatitis. 39<sup>th</sup> Annual Meeting of the European Association for the Study of the Liver, 2004, Berlin, Germany. (**Oral** presentation)
14. **Huang YH**, Tao MH, Hu Cp, Syu WJ, Wu JC. Identification of Novel HLA-A\*0201-restricted CD8 T-cell Epitopes on Hepatitis Delta Virus. The Gastroenterological Society of Taiwan 2004 Annual Convention (**Oral** presentation)
15. **Huang YH**, Hsu SC, Wang SY, Syu WJ, Wu JC. Varied immunity to large and small hepatitis delta antigens generated by DNA vaccine in mice-influence of the isoprenylated motif. 11<sup>th</sup> International Symposium on Viral Hepatitis & Liver Disease, 2003, Sydney Australia. (**Oral** presentation)

16. **Huang YH**, Wu JC, Hsu SC, Syu WJ. Varied immunity to large and small hepatitis delta antigens generated by DNA vaccine in mice. The Gastroenterological Society of Taiwan 2003 Annual Convention (**Oral** presentation)
17. **Huang YH**, Wu JC, Wang YJ, Chang TT, Sheen IJ, Huo TI, Chang FY, Lee SD. Evaluation of lamivudine in the treatment of patients with hepatitis b e antigen-negative chronic hepatitis b in Taiwan. The Gastroenterological Society of Taiwan 2002 Annual Convention (**Oral** presentation)
18. **Huang YH**, Wu JC, Sheen IJ, Chang FY, Lee SD. Establishment of a real-time detection system for hepatitis D virus genome quantitation. The Gastroenterological Society of Taiwan 2001 Annual Convention (**Oral** presentation)
19. **Huang YH**, Wu JC, Tao MH, Syu WJ, Hsu SC, Chi WK, Chang FY, Lee SD. DNA-based immunization produced Th1 immune responses to hepatitis delta virus in a mouse model. The Gastroenterological Society of Taiwan 2000 Annual Convention (**Oral** presentation).